首页 > 最新文献

Asian Biomedicine最新文献

英文 中文
Control of parenteral blood stream infections in patients who need parenteral nutrition. 控制需要肠外营养的病人的肠外血流感染。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0014
{"title":"Control of parenteral blood stream infections in patients who need parenteral nutrition.","authors":"","doi":"10.2478/abm-2024-0014","DOIUrl":"10.2478/abm-2024-0014","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"90-91"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prooxidant-antioxidant balance in diagnosis and developmental prognosis of premature neonates with asphyxia. 早产新生儿窒息诊断和发育预后中的原氧化剂-抗氧化剂平衡。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0017
Maryam Zakerihamidi, Boskabadi Hassan, Amirkhani Samin

Background: The antioxidant system in a preterm neonate is premature. The imbalance between the prooxidant and antioxidant systems can make these neonates prone to oxidative stress. Birth asphyxia is one of the factors that can disturb this balance.

Objective: We studied the prooxidant-antioxidant balance (PAB) in the diagnosis and developmental prognosis of preterm neonates with asphyxia.

Methods: This cohort study has been conducted between 2016 and 2022 with 2 years follow-up on 183 premature neonates admitted to Ghaem Hospital Mashhad, by using a convenience sampling method. The data-collection tool and the researcher-made checklist included the mothers' and the neonate's information, and the third segment included laboratory information. PAB was studied by using standard solutions and the Enzyme immunoassays (ELISA) method. After discharging the newborns from the hospital, they were under follow-up at 6 months, 12 months, 18 months, and 24 months, by using the Denver II test. PAB was compared among newborns with asphyxia, those without asphyxia, and also newborns with normal and abnormal outcomes in both groups.

Results: The mean ± standard deviation of the PAB factor reported is as follows: in newborns without asphyxia (21.00 ± 18.14 HK), those with asphyxia (31.00 ± 45.42 HK), in newborns with asphyxia having abnormal outcomes (40.00 ± 60.84 HK), and those having normal outcomes (21.00 ± 18.67 HK) (P ≤ 0.05). PAB results >25 HK have been used for the diagnosis of asphyxia prognosis in newborns, with 83.3% sensitivity and 81% specificity.

Conclusion: The PAB index showed a significant increase after asphyxia. It can be used as a diagnostic marker for the prognosis of premature newborns with asphyxia. Thus, diagnosis and prognosis of asphyxia in premature newborns can be predicted by using the PAB index.

背景:早产新生儿的抗氧化系统尚未发育成熟。促氧化系统和抗氧化系统之间的不平衡会使这些新生儿容易受到氧化应激。出生窒息是破坏这种平衡的因素之一:我们研究了早产新生儿窒息诊断和发育预后中的原氧化剂-抗氧化剂平衡(PAB):这项队列研究于 2016 年至 2022 年间进行,采用方便抽样法对马什哈德加埃姆医院收治的 183 名早产新生儿进行了为期 2 年的随访。数据收集工具和研究人员自制的核对表包括母亲和新生儿的信息,第三部分包括实验室信息。采用标准溶液和酶联免疫吸附(ELISA)方法对 PAB 进行了研究。新生儿出院后,在 6 个月、12 个月、18 个月和 24 个月时使用丹佛 II 测试对其进行随访。对两组窒息新生儿和非窒息新生儿以及结果正常和异常新生儿的 PAB 进行比较:结果:所报告的 PAB 因子的平均值 ± 标准偏差如下:无窒息的新生儿(21.00 ± 18.14 HK)、有窒息的新生儿(31.00 ± 45.42 HK)、有窒息且结果异常的新生儿(40.00 ± 60.84 HK)和结果正常的新生儿(21.00 ± 18.67 HK)(P ≤ 0.05)。PAB 结果大于 25 HK 已被用于新生儿窒息预后的诊断,其敏感性为 83.3%,特异性为 81%:结论:新生儿窒息后,PAB指数明显升高。结论:PAB 指数在窒息后明显升高,可作为早产新生儿窒息预后的诊断指标。因此,早产新生儿窒息的诊断和预后可通过 PAB 指数进行预测。
{"title":"The prooxidant-antioxidant balance in diagnosis and developmental prognosis of premature neonates with asphyxia.","authors":"Maryam Zakerihamidi, Boskabadi Hassan, Amirkhani Samin","doi":"10.2478/abm-2024-0017","DOIUrl":"10.2478/abm-2024-0017","url":null,"abstract":"<p><strong>Background: </strong>The antioxidant system in a preterm neonate is premature. The imbalance between the prooxidant and antioxidant systems can make these neonates prone to oxidative stress. Birth asphyxia is one of the factors that can disturb this balance.</p><p><strong>Objective: </strong>We studied the prooxidant-antioxidant balance (PAB) in the diagnosis and developmental prognosis of preterm neonates with asphyxia.</p><p><strong>Methods: </strong>This cohort study has been conducted between 2016 and 2022 with 2 years follow-up on 183 premature neonates admitted to Ghaem Hospital Mashhad, by using a convenience sampling method. The data-collection tool and the researcher-made checklist included the mothers' and the neonate's information, and the third segment included laboratory information. PAB was studied by using standard solutions and the Enzyme immunoassays (ELISA) method. After discharging the newborns from the hospital, they were under follow-up at 6 months, 12 months, 18 months, and 24 months, by using the Denver II test. PAB was compared among newborns with asphyxia, those without asphyxia, and also newborns with normal and abnormal outcomes in both groups.</p><p><strong>Results: </strong>The mean ± standard deviation of the PAB factor reported is as follows: in newborns without asphyxia (21.00 ± 18.14 HK), those with asphyxia (31.00 ± 45.42 HK), in newborns with asphyxia having abnormal outcomes (40.00 ± 60.84 HK), and those having normal outcomes (21.00 ± 18.67 HK) (<i>P</i> ≤ 0.05). PAB results >25 HK have been used for the diagnosis of asphyxia prognosis in newborns, with 83.3% sensitivity and 81% specificity.</p><p><strong>Conclusion: </strong>The PAB index showed a significant increase after asphyxia. It can be used as a diagnostic marker for the prognosis of premature newborns with asphyxia. Thus, diagnosis and prognosis of asphyxia in premature newborns can be predicted by using the PAB index.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"116-124"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disseminated gonococcal infection during two decades in the university hospital, Thailand. 泰国大学医院二十年间的淋球菌传播感染。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0018
Kanphai Wongjarit, Sittichai Ukritchon

Background: Disseminated gonococcal infection (DGI) caused by Neisseria gonorrhoeae commonly presents with the classic triad of polyarthritis, tenosynovitis, and dermatitis. There is no clinical and microbiological data of DGI in Thailand.

Objective: To study the clinical features, outcomes of treatments, and antimicrobial susceptibility data of DGI patients.

Methods: All medical records of DGI patients at King Chulalongkorn Memorial Hospital (KCMH) from January 2002 through September 2019 were reviewed and analyzed. The patients were defined as definite DGI (the clinical features and the evidence of gonococcal infection) and probable DGI (clinical features with response to treatment with third-generation cephalosporins and with no evidence of gonococcal infection).

Results: There were 41 patients (27 definite and 14 probable DGI), with a male-to-female ratio of 1:1.4 and median age of 30 years. The middle-age and elderly group accounted for 20% of the patients. The clinical features were fever (90.27%), arthritis (92.7%), tenosynovitis (63.4%), and genitourinary symptoms (29.3%). The most common pattern of joint involvement was oligoarthritis (52.6%). The majority of the patients had good clinical outcomes, while complications occurred in 4.8% of the patients including osteomyelitis and pyomyositis. All 19 antimicrobial-susceptibility results were susceptible to ceftriaxone.

Conclusions: During the past 2 decades in KCMH, the age of the DGI patients tends to be older, and there is no gender difference as in the historical studies. The clinical features are still similar to the previous studies. The majority of the patients had good clinical outcomes. There is no case of ceftriaxone-resistant N. gonorrhoeae.

背景:由淋病奈瑟菌引起的播散性淋球菌感染(DGI)通常表现为典型的三联征:多关节炎、腱鞘炎和皮炎。在泰国还没有关于 DGI 的临床和微生物学数据:研究 DGI 患者的临床特征、治疗效果和抗菌药物敏感性数据:回顾并分析2002年1月至2019年9月期间朱拉隆功国王纪念医院(KCMH)所有DGI患者的病历。患者被定义为明确的DGI(临床特征和淋球菌感染证据)和可能的DGI(临床特征对第三代头孢菌素治疗有反应,但无淋球菌感染证据):共有 41 名患者(27 人确诊,14 人疑似 DGI),男女比例为 1:1.4,中位年龄为 30 岁。中老年患者占 20%。临床特征为发热(90.27%)、关节炎(92.7%)、腱鞘炎(63.4%)和泌尿生殖系统症状(29.3%)。最常见的关节受累模式是少关节炎(52.6%)。大多数患者的临床疗效良好,4.8%的患者出现了并发症,包括骨髓炎和脓毒血症。所有 19 例抗菌药敏感结果均为头孢曲松敏感:结论:在过去 20 年中,KCMH 的 DGI 患者年龄趋于偏大,与历史研究中的性别差异无异。临床特征仍与之前的研究相似。大多数患者的临床疗效良好。没有出现对头孢曲松耐药的淋球菌病例。
{"title":"Disseminated gonococcal infection during two decades in the university hospital, Thailand.","authors":"Kanphai Wongjarit, Sittichai Ukritchon","doi":"10.2478/abm-2024-0018","DOIUrl":"10.2478/abm-2024-0018","url":null,"abstract":"<p><strong>Background: </strong>Disseminated gonococcal infection (DGI) caused by <i>Neisseria gonorrhoeae</i> commonly presents with the classic triad of polyarthritis, tenosynovitis, and dermatitis. There is no clinical and microbiological data of DGI in Thailand.</p><p><strong>Objective: </strong>To study the clinical features, outcomes of treatments, and antimicrobial susceptibility data of DGI patients.</p><p><strong>Methods: </strong>All medical records of DGI patients at King Chulalongkorn Memorial Hospital (KCMH) from January 2002 through September 2019 were reviewed and analyzed. The patients were defined as definite DGI (the clinical features and the evidence of gonococcal infection) and probable DGI (clinical features with response to treatment with third-generation cephalosporins and with no evidence of gonococcal infection).</p><p><strong>Results: </strong>There were 41 patients (27 definite and 14 probable DGI), with a male-to-female ratio of 1:1.4 and median age of 30 years. The middle-age and elderly group accounted for 20% of the patients. The clinical features were fever (90.27%), arthritis (92.7%), tenosynovitis (63.4%), and genitourinary symptoms (29.3%). The most common pattern of joint involvement was oligoarthritis (52.6%). The majority of the patients had good clinical outcomes, while complications occurred in 4.8% of the patients including osteomyelitis and pyomyositis. All 19 antimicrobial-susceptibility results were susceptible to ceftriaxone.</p><p><strong>Conclusions: </strong>During the past 2 decades in KCMH, the age of the DGI patients tends to be older, and there is no gender difference as in the historical studies. The clinical features are still similar to the previous studies. The majority of the patients had good clinical outcomes. There is no case of ceftriaxone-resistant <i>N. gonorrhoeae</i>.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"125-132"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of the immunological effects of escitalopram oxalate in the breast cancer co-culture model. 研究草酸艾司西酞普兰在乳腺癌共培养模型中的免疫学效应。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0019
Nalan Biriz, Zerrin Canturk

Background: During breast cancer treatment, approximately half of the patients are prescribed psychotropic medication, such as selective serotonin reuptake inhibitors (SSRIs). Escitalopram oxalate is an SSRI used as an antidepressant.

Objectives: In this study, by creating a breast cancer microenvironment with THP-1, MCF-7 and MDA-MB-231 breast cancer co-culture models were created.

Methods: MCF-7, MDA-MB-231, and THP-1 cell lines to determine the concentration range of the cytotoxic effect of escitalopram oxalate MTS and MTT test were used. IC50 values were determined by the xCELLigence real-time cell analysis (RTCA) system. Apoptotic activities and cytokine levels were determined by flow cytometry.

Results: In the xCELLigence real-time analysis made according to the results, the IC50 value of escitalopram oxalate was measured as 13.7 μM for MCF-7 and 10.9 μM for MDA-MB-231. The IC50 value was measured as 54.6 μM for MCF-7 and 58.4 μM for MDA-MB-231 in xCELLigence analysis with tamoxifen. According to the MTS test results, the IC50 value of tamoxifen for THP-1 was 92.03 μM and the IC50 value for escitalopram oxalate was 95.32 μM. In the co-culture model, the immunological effects of escitalopram oxalate on MCF-7 cells were 2.8%, 11.1%, 15.6%, 10.6%, and 12.1% for interleukin (IL)-1β, IL-6, IL-8, IL-10, and TNF-α, respectively, while MDA effects on MB-231 cells, respectively, were 2.1%, 15.9%, 16.2%, 8.8%, and 11.8%.

Conclusions: According to the results obtained, it was concluded that the immunological effects of escitalopram oxalate are more effective than tamoxifen and that it can be used as an adjunctive agent in breast cancer treatment.

背景:在乳腺癌治疗期间,约有一半的患者会被处方精神药物,如选择性5-羟色胺再摄取抑制剂(SSRIs)。草酸艾司西酞普兰是一种用作抗抑郁剂的 SSRI:在这项研究中,通过用 THP-1 创造乳腺癌微环境,创建了 MCF-7 和 MDA-MB-231 乳腺癌共培养模型:方法:使用 MCF-7、MDA-MB-231 和 THP-1 细胞系来确定草酸艾司西酞普兰细胞毒性作用的浓度范围。IC50 值由 xCELLigence 实时细胞分析(RTCA)系统确定。通过流式细胞术测定细胞凋亡活性和细胞因子水平:xCELLigence 实时分析结果显示,草酸艾司西酞普兰对 MCF-7 的 IC50 值为 13.7 μM,对 MDA-MB-231 的 IC50 值为 10.9 μM。在与他莫昔芬一起进行的 xCELLigence 分析中,测得 MCF-7 和 MDA-MB-231 的 IC50 值分别为 54.6 μM 和 58.4 μM。根据 MTS 测试结果,他莫昔芬对 THP-1 的 IC50 值为 92.03 μM,对草酸艾司西酞普兰的 IC50 值为 95.32 μM。在共培养模型中,草酸艾司西酞普兰对MCF-7细胞的白细胞介素(IL)-1β、IL-6、IL-8、IL-10和TNF-α的免疫学效应分别为2.8%、11.1%、15.6%、10.6%和12.1%,而对MB-231细胞的MDA效应分别为2.1%、15.9%、16.2%、8.8%和11.8%:根据研究结果,草酸艾司西酞普兰的免疫学效应比他莫昔芬更有效,可作为乳腺癌治疗的辅助药物。
{"title":"Investigation of the immunological effects of escitalopram oxalate in the breast cancer co-culture model.","authors":"Nalan Biriz, Zerrin Canturk","doi":"10.2478/abm-2024-0019","DOIUrl":"10.2478/abm-2024-0019","url":null,"abstract":"<p><strong>Background: </strong>During breast cancer treatment, approximately half of the patients are prescribed psychotropic medication, such as selective serotonin reuptake inhibitors (SSRIs). Escitalopram oxalate is an SSRI used as an antidepressant.</p><p><strong>Objectives: </strong>In this study, by creating a breast cancer microenvironment with THP-1, MCF-7 and MDA-MB-231 breast cancer co-culture models were created.</p><p><strong>Methods: </strong>MCF-7, MDA-MB-231, and THP-1 cell lines to determine the concentration range of the cytotoxic effect of escitalopram oxalate MTS and MTT test were used. IC<sub>50</sub> values were determined by the xCELLigence real-time cell analysis (RTCA) system. Apoptotic activities and cytokine levels were determined by flow cytometry.</p><p><strong>Results: </strong>In the xCELLigence real-time analysis made according to the results, the IC<sub>50</sub> value of escitalopram oxalate was measured as 13.7 μM for MCF-7 and 10.9 μM for MDA-MB-231. The IC<sub>50</sub> value was measured as 54.6 μM for MCF-7 and 58.4 μM for MDA-MB-231 in xCELLigence analysis with tamoxifen. According to the MTS test results, the IC<sub>50</sub> value of tamoxifen for THP-1 was 92.03 μM and the IC<sub>50</sub> value for escitalopram oxalate was 95.32 μM. In the co-culture model, the immunological effects of escitalopram oxalate on MCF-7 cells were 2.8%, 11.1%, 15.6%, 10.6%, and 12.1% for interleukin (IL)-1β, IL-6, IL-8, IL-10, and TNF-α, respectively, while MDA effects on MB-231 cells, respectively, were 2.1%, 15.9%, 16.2%, 8.8%, and 11.8%.</p><p><strong>Conclusions: </strong>According to the results obtained, it was concluded that the immunological effects of escitalopram oxalate are more effective than tamoxifen and that it can be used as an adjunctive agent in breast cancer treatment.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"133-145"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation. 肾移植中维持性免疫抑制方案的里程碑式研究综述。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0015
Suwasin Udomkarnjananun, Maaike R Schagen, Dennis A Hesselink

Immunosuppressive medications play a pivotal role in kidney transplantation, and the calcineurin inhibitors (CNIs), including cyclosporine A (CsA) and tacrolimus (TAC), are considered as the backbone of maintenance immunosuppressive regimens. Since the introduction of CNIs in kidney transplantation, the incidence of acute rejection has decreased, and allograft survival has improved significantly. However, CNI nephrotoxicity has been a major concern, believed to heavily impact long-term allograft survival and function. To address this concern, several CNI-sparing regimens were developed and studied in randomized, controlled, clinical trials, aiming to reduce CNI exposure and preserve long-term allograft function. However, more recent information has revealed that CNI nephrotoxicity is not the primary cause of late allograft failure, and its histopathology is neither specific nor pathognomonic. In this review, we discuss the historical development of maintenance immunosuppressive regimens in kidney transplantation, covering the early era of transplantation, the CNI-sparing era, and the current era where the alloimmune response, rather than CNI nephrotoxicity, appears to be the major contributor to late allograft failure. Our goal is to provide a chronological overview of the development of maintenance immunosuppressive regimens and summarize the most recent information for clinicians caring for kidney transplant recipients (KTRs).

免疫抑制药物在肾移植中起着举足轻重的作用,包括环孢素 A(CsA)和他克莫司(TAC)在内的钙神经蛋白抑制剂(CNIs)被认为是维持性免疫抑制方案的支柱。自在肾移植中引入 CNIs 以来,急性排斥反应的发生率有所下降,异体移植的存活率也显著提高。然而,氯化萘类药物的肾毒性一直是人们关注的主要问题,据信它会严重影响异体移植的长期存活和功能。为了解决这一问题,在随机对照临床试验中开发并研究了多种保留 CNI 的治疗方案,旨在减少 CNI 暴露,保护长期异体移植功能。然而,最近的信息显示,氯化萘肾毒性并不是晚期异体移植失败的主要原因,其组织病理学既非特异性也非病理标志性。在这篇综述中,我们讨论了肾移植中维持性免疫抑制方案的历史发展,包括早期移植时代、节省 CNI 时代和目前的时代,其中异体免疫反应而非 CNI 肾毒性似乎是导致晚期异体移植失败的主要原因。我们的目标是按时间顺序概述维持性免疫抑制方案的发展,并为护理肾移植受者(KTR)的临床医生总结最新信息。
{"title":"A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation.","authors":"Suwasin Udomkarnjananun, Maaike R Schagen, Dennis A Hesselink","doi":"10.2478/abm-2024-0015","DOIUrl":"10.2478/abm-2024-0015","url":null,"abstract":"<p><p>Immunosuppressive medications play a pivotal role in kidney transplantation, and the calcineurin inhibitors (CNIs), including cyclosporine A (CsA) and tacrolimus (TAC), are considered as the backbone of maintenance immunosuppressive regimens. Since the introduction of CNIs in kidney transplantation, the incidence of acute rejection has decreased, and allograft survival has improved significantly. However, CNI nephrotoxicity has been a major concern, believed to heavily impact long-term allograft survival and function. To address this concern, several CNI-sparing regimens were developed and studied in randomized, controlled, clinical trials, aiming to reduce CNI exposure and preserve long-term allograft function. However, more recent information has revealed that CNI nephrotoxicity is not the primary cause of late allograft failure, and its histopathology is neither specific nor pathognomonic. In this review, we discuss the historical development of maintenance immunosuppressive regimens in kidney transplantation, covering the early era of transplantation, the CNI-sparing era, and the current era where the alloimmune response, rather than CNI nephrotoxicity, appears to be the major contributor to late allograft failure. Our goal is to provide a chronological overview of the development of maintenance immunosuppressive regimens and summarize the most recent information for clinicians caring for kidney transplant recipients (KTRs).</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"92-108"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucocorticoid use and parenteral nutrition are risk factors for catheter-related Candida bloodstream infection: a retrospective study. 使用糖皮质激素和肠外营养是导管相关念珠菌血流感染的风险因素:一项回顾性研究。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0016
Lipeng Huang, Shanshan Li, Ronglin Jiang, Shu Lei, Jiannong Wu, Liquan Huang, Meifei Zhu

Background: Catheter-related candidemia (CRC) is a serious catheter-related bloodstream infection (CRBSI) caused by Candida spp., with higher mortality than CRBSIs caused by other organisms.

Objective: To identify the risk factors for Candida CRBSI. The clinical characteristics of 297 patients with CRBSI in a local hospital from January 2007 to June 2015 were collected, including 33 Candida CRBSI and 264 non-Candida CRBSI.

Method: The associations of Candida CRBSI with the clinical variables were examined using univariate and multivariate analyses.

Results: Multivariate analysis showed that glucocorticoid use (odds ratio [OR] = 10.313, 95% confidence interval [CI] = 2.032-52.330, P = 0.005) and parenteral nutrition (OR = 5.400, 95% CI = 0.472-61.752, P = 0.0175) were independent risk factors for Candida CRBSI. The most prevalent species were Candida tropicalis (42.4%) and Candida albicans (36.36%). Of the 33 Candida CRBSI cases, 31 (93.93%) had indwelling central venous catheters (CVC) for ≥14 d. The mortality of Candida CRBSI was remarkably higher than that of bacteria CRBSI. Patients with timely catheter removal and appropriate antifungal treatment had dramatically increased 28-d survival compared with those with untimely catheter removal + inappropriate antifungal treatment (88.89% vs. 0, P = 0.006).

Conclusion: The study identified glucocorticoid use and parenteral nutrition as independent risk factors for Candida CRBSI. The outcome of candidemia was associated with the duration of CVC indwelling and antifungal treatment.

背景:导管相关念珠菌血症(CRC)是由念珠菌属引起的一种严重的导管相关血流感染(CRBSI),其死亡率高于由其他微生物引起的CRBSI:目的:确定念珠菌 CRBSI 的风险因素。收集了当地一家医院2007年1月至2015年6月期间297例CRBSI患者的临床特征,其中包括33例念珠菌CRBSI和264例非念珠菌CRBSI:方法:采用单变量和多变量分析研究念珠菌CRBSI与临床变量的关系:多变量分析显示,使用糖皮质激素(几率比 [OR] = 10.313,95% 置信区间 [CI] = 2.032-52.330,P = 0.005)和肠外营养(OR = 5.400,95% CI = 0.472-61.752,P = 0.0175)是念珠菌 CRBSI 的独立危险因素。最常见的念珠菌为热带念珠菌(42.4%)和白念珠菌(36.36%)。在33例念珠菌CRBSI病例中,31例(93.93%)留置中心静脉导管(CVC)≥14天。与未及时拔除导管+抗真菌治疗不当的患者相比,及时拔除导管并接受适当抗真菌治疗的患者 28 天存活率大幅提高(88.89% vs. 0,P = 0.006):研究发现,使用糖皮质激素和肠外营养是念珠菌 CRBSI 的独立风险因素。念珠菌血症的结果与CVC留置时间和抗真菌治疗有关。
{"title":"Glucocorticoid use and parenteral nutrition are risk factors for catheter-related <i>Candida</i> bloodstream infection: a retrospective study.","authors":"Lipeng Huang, Shanshan Li, Ronglin Jiang, Shu Lei, Jiannong Wu, Liquan Huang, Meifei Zhu","doi":"10.2478/abm-2024-0016","DOIUrl":"10.2478/abm-2024-0016","url":null,"abstract":"<p><strong>Background: </strong>Catheter-related candidemia (CRC) is a serious catheter-related bloodstream infection (CRBSI) caused by <i>Candida</i> spp., with higher mortality than CRBSIs caused by other organisms.</p><p><strong>Objective: </strong>To identify the risk factors for <i>Candida</i> CRBSI. The clinical characteristics of 297 patients with CRBSI in a local hospital from January 2007 to June 2015 were collected, including 33 <i>Candida</i> CRBSI and 264 non-<i>Candida</i> CRBSI.</p><p><strong>Method: </strong>The associations of <i>Candida</i> CRBSI with the clinical variables were examined using univariate and multivariate analyses.</p><p><strong>Results: </strong>Multivariate analysis showed that glucocorticoid use (odds ratio [OR] = 10.313, 95% confidence interval [CI] = 2.032-52.330, <i>P</i> = 0.005) and parenteral nutrition (OR = 5.400, 95% CI = 0.472-61.752, <i>P</i> = 0.0175) were independent risk factors for <i>Candida</i> CRBSI. The most prevalent species were <i>Candida tropicalis</i> (42.4%) and <i>Candida albicans</i> (36.36%). Of the 33 <i>Candida</i> CRBSI cases, 31 (93.93%) had indwelling central venous catheters (CVC) for ≥14 d. The mortality of <i>Candida</i> CRBSI was remarkably higher than that of bacteria CRBSI. Patients with timely catheter removal and appropriate antifungal treatment had dramatically increased 28-d survival compared with those with untimely catheter removal + inappropriate antifungal treatment (88.89% vs. 0, <i>P</i> = 0.006).</p><p><strong>Conclusion: </strong>The study identified glucocorticoid use and parenteral nutrition as independent risk factors for <i>Candida</i> CRBSI. The outcome of candidemia was associated with the duration of CVC indwelling and antifungal treatment.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"109-115"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memory of Professor Henry Wilde, MD, FACP: infectious disease physician, clinical and public health investigator, and educator. 悼念亨利-王尔德教授(医学博士、全科医生):传染病医生、临床和公共卫生调查员以及教育家。
IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.2478/abm-2024-0013
{"title":"In memory of Professor Henry Wilde, MD, FACP: infectious disease physician, clinical and public health investigator, and educator.","authors":"","doi":"10.2478/abm-2024-0013","DOIUrl":"10.2478/abm-2024-0013","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"18 3","pages":"87-89"},"PeriodicalIF":0.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo 用 pGCsiRNA 血管内皮生长因子治疗体内胆管癌
IF 0.6 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-05-02 DOI: 10.2478/abm-2024-0009
Shenglin Lu, Jun Li
Background The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice. Objectives To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF. Methods The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated Salmonella carrying the plasmid pGCsiRNA-VEGF. One month later, the tumor volume of nude mice was observed, and the tumor growth curve was plotted. The harvested tumors were weighed and detected for tissue structural changes and cell death status by hematoxylin–eosin staining. The protein and mRNA expressions of VEGF, matrix metalloproteinase 2 (MMP2), and MMP9 were detected by Western blotting and PCR, respectively. Results The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (P < 0.05). The expressions of VEGF, MMP2, and MMP9 at the transcriptional and translational levels were inhibited by pGCsiRNA-VEGF. PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure. Conclusions In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.
背景 在临床实践中使用特异性肿瘤标志物可能有利于胆管癌的早期诊断和治疗。目的 利用携带 pGCsiRNA-VEGF 质粒的减毒沙门氏菌对裸鼠胆管癌模型进行靶向治疗,研究 pGCsiRNA-血管内皮生长因子(VEGF)能否影响胆管癌的发生和发展及其可能的机制。方法 通过尾静脉注射 QBC939 细胞和携带 pGCsiRNA-VEGF 质粒的减毒沙门氏菌,建立胆管癌裸鼠模型。一个月后,观察裸鼠的肿瘤体积并绘制肿瘤生长曲线。对收获的肿瘤进行称重,并通过苏木精-伊红染色检测组织结构变化和细胞死亡状况。通过 Western 印迹和 PCR 分别检测血管内皮生长因子、基质金属蛋白酶 2(MMP2)和 MMP9 的蛋白和 mRNA 表达。结果 pGCsiRNA-VEGF 组的肿瘤体积和重量明显小于模拟组和 si-scramble 组(P < 0.05)。pGCsiRNA-VEGF 在转录和翻译水平上抑制了 VEGF、MMP2 和 MMP9 的表达。PGCsiRNA-VEGF 促进了组织凋亡并破坏了组织结构。结论 在体内沉默 VEGF 可影响细胞存活并抑制细胞迁移、侵袭和发育,这可能是通过增强细胞凋亡和抑制 MMP2 和 MMP9 的表达实现的。
{"title":"Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo","authors":"Shenglin Lu, Jun Li","doi":"10.2478/abm-2024-0009","DOIUrl":"https://doi.org/10.2478/abm-2024-0009","url":null,"abstract":"Background The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice. Objectives To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated <jats:italic>Salmonella</jats:italic> carrying the plasmid pGCsiRNA-VEGF. Methods The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated <jats:italic>Salmonella</jats:italic> carrying the plasmid pGCsiRNA-VEGF. One month later, the tumor volume of nude mice was observed, and the tumor growth curve was plotted. The harvested tumors were weighed and detected for tissue structural changes and cell death status by hematoxylin–eosin staining. The protein and mRNA expressions of VEGF, matrix metalloproteinase 2 (MMP2), and MMP9 were detected by Western blotting and PCR, respectively. Results The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (<jats:italic>P</jats:italic> &lt; 0.05). The expressions of VEGF, MMP2, and MMP9 at the transcriptional and translational levels were inhibited by pGCsiRNA-VEGF. PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure. Conclusions In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"113 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140834644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal final adult height achieved by low-dose recombinant human growth hormone therapy 通过低剂量重组人生长激素疗法达到最佳最终成人身高
IF 0.6 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-05-02 DOI: 10.2478/abm-2024-0011
Tansit Saengkaew, Suparb Aroonparkmongkol, Suttipong Wacharasindhu
Background Thailand has been administering the recombinant human growth hormone (rhGH) treatment for >20 years. Due to limited resources being available, efforts have been directed toward utilizing rhGH at the lowest feasible dose. However, there is currently a lack of evidence in terms of the efficacy and outcomes. Objective To evaluate the auxological outcomes of growth hormone (GH) treatment and the GH secretion ability after reaching final adult height (FAH) and discontinuing rhGH. Methods Data of 40 patients were retrospectively reviewed. The clinical characteristics, auxological data, and results of biochemical and endocrine investigations before and during rhGH treatment were evaluated. In addition, GH retesting was performed in 24 patients using the insulin tolerance test. Results Twenty patients (50%) had complete growth hormone deficiency (GHD), defined as peak stimulated GH level <5 ng/mL, and the remaining patients had partial GHD. Most patients were male (n = 25, 62.5%). The mean age at which rhGH was initiated was 8.9 years. Patients with partial GHD received a higher dose of rhGH than those with complete GHD (30.9 µg/kg/d vs. 26.2 µg/kg/d, P = 0.02). Patients with complete and partial GHD reached FAH at height standard deviation scores (SDSs) of −0.65 and −1.47, respectively. The factors associated with obtaining a good clinical response in terms of height gain included peak-stimulated GH level, age of puberty, and age of discontinuing rhGH. After completing the rhGH treatment, 13 of the 24 patients showed normal GH secretion. Patients with multiple pituitary hormone deficiency (MPHD) were likely to have persistent GHD through adulthood (n = 8, 88.9%). Conclusion This study has demonstrated that the use of low-dose rhGH could result in healthy populations achieving optimal FAHs. Patients with MPHD might not require retesting as they were likely to have persistent GHD. The results obtained in this research highlight the benefits of the treatment. This treatment can be applied in resource-limited countries.
背景 泰国采用重组人生长激素(rhGH)治疗已有 20 年历史。由于资源有限,人们一直致力于以最低可行剂量使用 rhGH。然而,目前在疗效和结果方面缺乏证据。目的 评估生长激素(GH)治疗的辅助治疗效果以及达到最终成人身高(FAH)并停用rhGH后的GH分泌能力。方法 回顾性分析 40 例患者的数据。评估了rhGH治疗前和治疗期间的临床特征、辅助检查数据以及生化和内分泌检查结果。此外,还使用胰岛素耐量试验对24名患者进行了GH复测。结果 20名患者(50%)患有完全性生长激素缺乏症(GHD),即刺激性GH峰值水平为5纳克/毫升,其余患者为部分性GHD。大多数患者为男性(n = 25,62.5%)。开始使用rhGH的平均年龄为8.9岁。与完全性GHD患者相比,部分GHD患者接受的rhGH剂量更高(30.9 µg/kg/d vs. 26.2 µg/kg/d,P = 0.02)。完全性和部分性GHD患者在身高标准偏差评分(SDS)分别为-0.65和-1.47时达到FAH。在身高增长方面获得良好临床反应的相关因素包括GH刺激峰值水平、青春期年龄和停用rhGH的年龄。完成rhGH治疗后,24名患者中有13人的GH分泌正常。多发性垂体激素缺乏症(MPHD)患者很可能在成年后持续存在GHD(8例,88.9%)。结论 本研究表明,使用低剂量 rhGH 可使健康人群达到最佳 FAHs。多发性多器官功能障碍患者可能不需要重新检测,因为他们很可能患有持续性多发性多器官功能障碍。这项研究获得的结果凸显了治疗的益处。这种治疗方法可用于资源有限的国家。
{"title":"Optimal final adult height achieved by low-dose recombinant human growth hormone therapy","authors":"Tansit Saengkaew, Suparb Aroonparkmongkol, Suttipong Wacharasindhu","doi":"10.2478/abm-2024-0011","DOIUrl":"https://doi.org/10.2478/abm-2024-0011","url":null,"abstract":"Background Thailand has been administering the recombinant human growth hormone (rhGH) treatment for &gt;20 years. Due to limited resources being available, efforts have been directed toward utilizing rhGH at the lowest feasible dose. However, there is currently a lack of evidence in terms of the efficacy and outcomes. Objective To evaluate the auxological outcomes of growth hormone (GH) treatment and the GH secretion ability after reaching final adult height (FAH) and discontinuing rhGH. Methods Data of 40 patients were retrospectively reviewed. The clinical characteristics, auxological data, and results of biochemical and endocrine investigations before and during rhGH treatment were evaluated. In addition, GH retesting was performed in 24 patients using the insulin tolerance test. Results Twenty patients (50%) had complete growth hormone deficiency (GHD), defined as peak stimulated GH level &lt;5 ng/mL, and the remaining patients had partial GHD. Most patients were male (n = 25, 62.5%). The mean age at which rhGH was initiated was 8.9 years. Patients with partial GHD received a higher dose of rhGH than those with complete GHD (30.9 µg/kg/d vs. 26.2 µg/kg/d, <jats:italic>P</jats:italic> = 0.02). Patients with complete and partial GHD reached FAH at height standard deviation scores (SDSs) of −0.65 and −1.47, respectively. The factors associated with obtaining a good clinical response in terms of height gain included peak-stimulated GH level, age of puberty, and age of discontinuing rhGH. After completing the rhGH treatment, 13 of the 24 patients showed normal GH secretion. Patients with multiple pituitary hormone deficiency (MPHD) were likely to have persistent GHD through adulthood (n = 8, 88.9%). Conclusion This study has demonstrated that the use of low-dose rhGH could result in healthy populations achieving optimal FAHs. Patients with MPHD might not require retesting as they were likely to have persistent GHD. The results obtained in this research highlight the benefits of the treatment. This treatment can be applied in resource-limited countries.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"24 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140835061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetic resonance imaging findings of a case with Wolffian tumor and related literature review 一例沃尔夫瘤患者的磁共振成像结果及相关文献综述
IF 0.6 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-05-02 DOI: 10.2478/abm-2024-0012
Can Cui, Dawei Cui, Jiangfeng Pan, Shaobin Zhou, Xiujuan Zheng
Background Wolffian tumors in females are rare gynecological neoplasms, with fewer than 100 cases reported. Existing literature primarily focuses on the pathology, and reports involving imaging are limited. Objective This study presents a case of Wolffian tumor, emphasizing its magnetic resonance imaging (MRI) characteristics to enhance preoperative diagnostic accuracy. Case report A 56-year-old woman presented with a year-long history of irregular vaginal bleeding. MRI revealed a solid mass in the right adnexal region. On T2-weighted images, the mass exhibited slightly elevated signal intensity with a distinctive low-signal intensity rim. Diffusion-weighted imaging displayed markedly increased signal intensity, and the contrast enhancement was moderate. The patient underwent laparoscopic right adnexectomy and received a Wolffian tumor diagnosis. No recurrence was observed during a 6-month follow-up. Conclusions Wolffian tumors exhibit distinctive MRI presentations. Notably, the prominent low-signal intensity rim on MRI may aid in accurate preoperative tumor diagnosis.
背景 女性沃尔夫氏肿瘤是一种罕见的妇科肿瘤,目前报道的病例不到 100 例。现有文献主要集中在病理学方面,涉及影像学的报道有限。本研究介绍一例沃尔夫瘤,强调其磁共振成像(MRI)特征,以提高术前诊断的准确性。病例报告 一位 56 岁的女性患者有一年的不规则阴道出血史。核磁共振成像显示右侧附件区有一个实性肿块。T2 加权成像显示,肿块信号强度略有升高,并伴有明显的低信号强度边缘。弥散加权成像显示信号强度明显增高,对比度中度增强。患者接受了腹腔镜右附件切除术,并得到了沃尔夫肿瘤的诊断。在 6 个月的随访中未发现复发。结论 沃尔夫肿瘤的磁共振成像表现与众不同。值得注意的是,核磁共振成像上突出的低信号强度边缘有助于术前准确诊断肿瘤。
{"title":"Magnetic resonance imaging findings of a case with Wolffian tumor and related literature review","authors":"Can Cui, Dawei Cui, Jiangfeng Pan, Shaobin Zhou, Xiujuan Zheng","doi":"10.2478/abm-2024-0012","DOIUrl":"https://doi.org/10.2478/abm-2024-0012","url":null,"abstract":"Background Wolffian tumors in females are rare gynecological neoplasms, with fewer than 100 cases reported. Existing literature primarily focuses on the pathology, and reports involving imaging are limited. Objective This study presents a case of Wolffian tumor, emphasizing its magnetic resonance imaging (MRI) characteristics to enhance preoperative diagnostic accuracy. Case report A 56-year-old woman presented with a year-long history of irregular vaginal bleeding. MRI revealed a solid mass in the right adnexal region. On T2-weighted images, the mass exhibited slightly elevated signal intensity with a distinctive low-signal intensity rim. Diffusion-weighted imaging displayed markedly increased signal intensity, and the contrast enhancement was moderate. The patient underwent laparoscopic right adnexectomy and received a Wolffian tumor diagnosis. No recurrence was observed during a 6-month follow-up. Conclusions Wolffian tumors exhibit distinctive MRI presentations. Notably, the prominent low-signal intensity rim on MRI may aid in accurate preoperative tumor diagnosis.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"11 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140835062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asian Biomedicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1